A retrospective analysis for the predictive factors for severe adverse event in the patients of advanced non-small cell lung cancer who treated with anti-PD-1 antibody

A retrospective analysis for the predictive factors for severe adverse event in the patients of advanced non-small cell lung cancer who treated with anti-PD-1 antibody - Adverse events of anti-PD-1 antibody and predictive factors in patients with lung cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000033826

Enrollment

Registered

2018-08-20

Start date

2018-08-21

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-small cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients in whom NSCLC had been histologically diagnosed from January 2016 to February 2018 at Kansai Medical University Medical Center and treated with anti-PD-1 antibody.

Exclusion criteria

Exclusion criteria: Patients refused to participate of this study, judged as inappropriate by principal investigator.

Design outcomes

Primary

Measure	Time frame
incidence of severe adverse events	—

Secondary

Measure	Time frame
response rate, progression-free survival	—

Countries

Japan

Contacts

Public ContactTakeshi Tamaki

Kansai Medical University Medical Center First Department of Internal Medicine

tamakit@takii.kmu.ac.jp06-6992-1001

Outcome results